These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 35784565)

  • 21. Glucagon Control on Food Intake and Energy Balance.
    Al-Massadi O; Fernø J; Diéguez C; Nogueiras R; Quiñones M
    Int J Mol Sci; 2019 Aug; 20(16):. PubMed ID: 31405212
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Repositioning Glucagon Action in the Physiology and Pharmacology of Diabetes.
    Finan B; Capozzi ME; Campbell JE
    Diabetes; 2020 Apr; 69(4):532-541. PubMed ID: 31178432
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hypoglycemic Effect of Combined Ghrelin and Glucagon Receptor Blockade.
    Mani BK; Uchida A; Lee Y; Osborne-Lawrence S; Charron MJ; Unger RH; Berglund ED; Zigman JM
    Diabetes; 2017 Jul; 66(7):1847-1857. PubMed ID: 28487437
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Glucagon-like peptide 1/glucagon receptor dual agonism reverses obesity in mice.
    Pocai A; Carrington PE; Adams JR; Wright M; Eiermann G; Zhu L; Du X; Petrov A; Lassman ME; Jiang G; Liu F; Miller C; Tota LM; Zhou G; Zhang X; Sountis MM; Santoprete A; Capito' E; Chicchi GG; Thornberry N; Bianchi E; Pessi A; Marsh DJ; SinhaRoy R
    Diabetes; 2009 Oct; 58(10):2258-66. PubMed ID: 19602537
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Chronic treatment with exendin(9-39)amide indicates a minor role for endogenous glucagon-like peptide-1 in metabolic abnormalities of obesity-related diabetes in ob/ob mice.
    Green BD; Irwin N; Gault VA; Bailey CJ; O'Harte FP; Flatt PR
    J Endocrinol; 2005 May; 185(2):307-17. PubMed ID: 15845923
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Somatostatin and diabetes.
    Gerich JE
    Am J Med; 1981 Mar; 70(3):619-26. PubMed ID: 6111219
    [TBL] [Abstract][Full Text] [Related]  

  • 27. ["Glucagon-like peptide I": a therapeutic alternative for diabetes mellitus?].
    Fehmann HC; Göke B
    Dtsch Med Wochenschr; 1994 Feb; 119(8):275-9. PubMed ID: 8112212
    [No Abstract]   [Full Text] [Related]  

  • 28. Benefits and limitations of reducing glucagon action for the treatment of type 2 diabetes.
    Ali S; Drucker DJ
    Am J Physiol Endocrinol Metab; 2009 Mar; 296(3):E415-21. PubMed ID: 19116373
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Defective insulin secretion by chronic glucagon receptor activation in glucose intolerant mice.
    Ahlkvist L; Omar B; Valeur A; Fosgerau K; Ahrén B
    J Endocrinol; 2016 Mar; 228(3):171-8. PubMed ID: 26698567
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Physiology and pathophysiology of glucagon-like peptide-1 (GLP-1): the role of GLP-1 in the pathogenesis of diabetes mellitus, obesity, and stress.
    Bojanowska E
    Med Sci Monit; 2005 Aug; 11(8):RA271-8. PubMed ID: 16049395
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pleiotropic effects of glucagon-like peptide-1 (GLP-1)-based therapies on vascular complications in diabetes.
    Yamagishi S; Matsui T
    Curr Pharm Des; 2011 Dec; 17(38):4379-85. PubMed ID: 22204436
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bioactive GLP-1 in gut, receptor expression in pancreas, and insulin response to GLP-1 in diabetes-prone rats.
    Valverde I; Wang GS; Burghardt K; Kauri LM; Redondo A; Acitores A; Villanueva-Peñacarrillo ML; Courtois P; Sener A; Cancelas J; Malaisse WJ; Scott FW
    Endocrine; 2004 Feb; 23(1):77-84. PubMed ID: 15034199
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Minireview: Glucagon in the pathogenesis of hypoglycemia and hyperglycemia in diabetes.
    Cryer PE
    Endocrinology; 2012 Mar; 153(3):1039-48. PubMed ID: 22166985
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Targeting glucagon receptor signalling in treating metabolic syndrome and renal injury in Type 2 diabetes: theory versus promise.
    Li XC; Zhuo JL
    Clin Sci (Lond); 2007 Aug; 113(4):183-93. PubMed ID: 17623014
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mechanisms of action of glucagon-like peptide 1 in the pancreas.
    Doyle ME; Egan JM
    Pharmacol Ther; 2007 Mar; 113(3):546-93. PubMed ID: 17306374
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [The physiology of glucagon-like peptide-1 and its role in the pathophysiology of type 2 diabetes mellitus].
    Escalada FJ
    Med Clin (Barc); 2014 Sep; 143 Suppl 2():2-7. PubMed ID: 25437458
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Glucagon and regulation of glucose metabolism.
    Jiang G; Zhang BB
    Am J Physiol Endocrinol Metab; 2003 Apr; 284(4):E671-8. PubMed ID: 12626323
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Metabolic manifestations of insulin deficiency do not occur without glucagon action.
    Lee Y; Berglund ED; Wang MY; Fu X; Yu X; Charron MJ; Burgess SC; Unger RH
    Proc Natl Acad Sci U S A; 2012 Sep; 109(37):14972-6. PubMed ID: 22891336
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A novel glucagon-like peptide-1/glucagon receptor dual agonist exhibits weight-lowering and diabetes-protective effects.
    Zhou J; Cai X; Huang X; Dai Y; Sun L; Zhang B; Yang B; Lin H; Huang W; Qian H
    Eur J Med Chem; 2017 Sep; 138():1158-1169. PubMed ID: 28772236
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Team Players or Opponents: Coadministration of Selective Glucagon and GLP-1 Receptor Agonists in Obese Diabetic Monkeys.
    Elvert R; Bossart M; Herling AW; Weiss T; Zhang B; Kannt A; Wagner M; Haack T; Evers A; Dudda A; Keil S; Lorenz M; Lorenz K; Riz M; Hennerici W; Larsen PJ
    Endocrinology; 2018 Aug; 159(8):3105-3119. PubMed ID: 29992313
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.